Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Publication Type:
Journal Article
Source:
N Engl J Med, Volume 370, Issue 3, p.211-221 (2014)
Keywords:
Adult,
adverse effects,
Aged,
analogs & derivatives,
analysis,
antagonists & inhibitors,
Antiviral Agents,
Baltimore,
boceprevir,
California,
chronic HCV,
Cities,
Colorado,
drug effects,
drug therapy,
Drug Therapy,Combination,
Fatigue,
Female,
Florida,
genetics,
Genotype,
genotype 1,
HCV,
Headache,
Health,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Humans,
Imidazoles,
immunology,
Infection,
isolation & purification,
Liver,
Male,
methods,
Michigan,
Middle Aged,
Multicenter Studies,
Nausea,
New Jersey,
New York,
Patients,
peginterferon,
Philadelphia,
protease inhibitor,
Protease Inhibitors,
Proteins,
Puerto Rico,
Research,
Research Support,
Ribavirin,
Rna,
Rna,Viral,
sofosbuvir,
sustained virologic response,
Telaprevir,
Texas,
therapeutic use,
therapy,
treatment,
Universities,
Uridine,
Uridine Monophosphate,
Viral Nonstructural Proteins,
Young Adult
